Douglas Pharmaceuticals hail ‘breakthrough’ for treatment-resistant depression
+News
Douglas Pharmaceuticals hail ‘breakthrough’ for treatment-resistant depression
Pharmacy Today
Tuesday 15 June 2021, 04:11 PM
The early phase of the Douglas study saw 234 patients with treatment-resistant depression being given extended-release oral doses of ketamine [photo: Nik Shuliahin on Unsplash]
Douglas Pharmaceuticals is heralding early results of its trial on using ketamine to treat depression as possibly the most significant step in the fie
Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management